Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-5552 Monotherapy in Advanced Solid Tumors
NCT04774952Phase 1Completed
- Sponsor
- Revolution Medicines
- Start
- Apr 2021
- Primary completion
- May 2024
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RMC-5552 in solid tumor, sponsored by Revolution Medicines. Primary endpoints: Number of participants with adverse events up to 3 years and Number of participants with dose limiting toxicities at 21 days. Started Apr 2021; status: completed.
02
Drugs
RMC-5552
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04774952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774952.